Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Clinical trial NCT05281471 · RECRUITING

Trial details

NCT number: NCT05281471
Sponsor: Genelux Corporation
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Platinum-resistant Ovarian Cancer Platinum-refractory Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer High-grade Serous Ovarian Cancer Endometrioid Ovarian Cancer Ovarian Clear Cell Carcinoma

Start date: 2022-08-31
Primary completion: 2026-12-01
Enrollment: 186

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.